Repeated-dose toxicity of HSP27-binding heptapeptide in mice

Hae June Lee, Yun Sil Lee

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Heptapeptide, including seven amino acids of the PKCδ V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin (Kim et al., 2007), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.

Original languageEnglish
Pages (from-to)284-290
Number of pages7
JournalDrug and Chemical Toxicology
Issue number3
StatePublished - Jul 2010

Bibliographical note

Funding Information:
This study was supported by a grant from the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare, and Family Affairs (A080997) and by a grant from the Nuclear Research and Development Program of the National Research Foundation of the Ministry for Education, Science, and Technology (grant code: M2AMA006) of the Korean government. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.


  • Heptapeptide
  • HSP27
  • PCKδ
  • Safety
  • Toxicology


Dive into the research topics of 'Repeated-dose toxicity of HSP27-binding heptapeptide in mice'. Together they form a unique fingerprint.

Cite this